Nasal spray formulations containing sumatriptan act as selective serotonin receptor agonists (5-HT1B/1D) that cause vasoconstriction and inhibit neurogenic inflammation in cerebral blood vessels. When administered intranasally for cluster headache, these medications provide rapid onset of action, quickly crossing the blood-brain barrier to abort acute attacks by reducing pain signal transmission and decreasing inflammatory mediators.